文献速递泌尿男性生殖肿瘤

阿替利珠单抗单药对比化疗一线治疗局部晚期或转移性尿路上皮癌(IMvigor130):随机对照3期研究的最终总生存分析

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
PubMed 文献 · Lancet Oncol · 2023-12-12

IMvigor130研究在35个国家221家医院入组1213例初治局部晚期或转移性尿路上皮癌患者,随机分为阿替利珠单抗联合铂类化疗(A组)、阿替利珠单抗单药(B组)和安慰剂联合铂类化疗(C组)。本次报告B组与C组最终总生存分析:B组中位总生存15.2个月,C组13.3个月,分层风险比0.98(95%CI 0.82-1.16),意向治疗人群未见显著改善,报告为描述性和探索性。

要点

  • B组中位总生存15.2个月 vs C组13.3个月,分层HR 0.98(95%CI 0.82-1.16),无显著改善。
  • 阿替利珠单抗单药3-4级治疗相关不良事件以贫血(1% vs 34%)等血液学事件为主,低于化疗组。
  • 该分析为描述性和探索性,安全性随访延长后未发现新安全信号。

核心结论

  • 最终分析显示,在意向治疗人群中,一线阿替利珠单抗单药对比铂类化疗未显著改善总生存,分层风险比0.98(95%CI 0.82-1.16)。
  • 阿替利珠单抗单药在延长随访后安全性仍可接受,未出现新的安全信号。

研究设计与样本

  • 全球、部分盲法、随机对照3期研究,35个国家221家医院和肿瘤中心入组,患者年龄≥18岁、局部晚期或转移性尿路上皮癌且转移阶段未接受过治疗、ECOG体能状态0-2。
  • 按1:1:1随机分为阿替利珠单抗联合铂类化疗(A组)、阿替利珠单抗单药(B组)、安慰剂联合铂类化疗(C组),按PD-L1状态、Bajorin评分和研究者选择的铂类化疗分层。
  • A组和C组对阿替利珠单抗或安慰剂设盲,B组阿替利珠单抗单药为开放标签;B组和C组阿替利珠单抗1200 mg或安慰剂每3周静脉给药。
  • 化疗为21天周期:吉西他滨1000 mg/m2体表面积第1天和第8天,联合研究者选择的卡铂(曲线下面积4.5 mg/mL每分或5 mg/mL每分)或顺铂70 mg/m2体表面积静脉给药。
  • 本次B组与C组总生存分析纳入同时入组的B组360例和C组359例意向治疗人群;安全性分析纳入两组所有接受研究治疗的患者。

主要发现

  • 2016年7月15日至2018年7月20日共1213例患者入组随机,B组362例、C组400例,其中同时入组者分别为360例和359例(意向治疗人群)。
  • 意向治疗人群中男性543例(76%)、女性176例(24%),白人534例(74%)。
  • 截至2022年8月31日数据截止,中位随访13.4个月(IQR 6.2-30.8),B组中位总生存15.2个月(95%CI 13.1-17.7;271例死亡),C组13.3个月(95%CI 11.9-15.6;275例死亡),分层风险比0.98(95%CI 0.82-1.16)。
  • 常见3-4级治疗相关不良事件:贫血接受阿替利珠单抗单药者2例(1%)vs 接受安慰剂联合化疗者133例(34%),中性粒细胞减少1例(<1%)vs 115例(30%),中性粒细胞计数降低0例 vs 95例(24%),血小板计数降低1例(<1%)vs 92例(24%)。
  • 严重不良事件163例(46%)vs 196例(50%);治疗相关死亡接受阿替利珠单抗单药者3例(1%;肺炎、间质性肺病、大肠梗阻各1例),接受安慰剂联合化疗者4例(1%;腹泻、发热性中性粒细胞减少、不明原因死亡、中毒性肝炎各1例)。

关键数值与推荐

  • B组与C组总生存为共同主要终点之一,因A组与C组最终分析未达显著总生存获益,本报告为描述性、应视为探索性。
  • B组中位总生存15.2个月(95%CI 13.1-17.7;271例死亡)vs C组13.3个月(95%CI 11.9-15.6;275例死亡),分层风险比0.98(95%CI 0.82-1.16)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本报告为描述性分析,因研究统计设计应视为探索性,未对B组与C组进行正式统计学检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary analysis of IMvigor130 showed a significant progression-free survival benefit with first-line atezolizumab plus platinum-based chemotherapy (group A) versus placebo plus platinum-based chemotherapy (group C) in patients with locally advanced or metastatic urothelial cancer. However, this finding did not translate into significant overall survival benefit for group A versus group C at the final analysis, precluding formal statistical testing of outcomes with atezolizumab monotherapy (group B) versus group C. Here we report the final overall survival results for group B versus group C; this report is descriptive and should be considered exploratory due to the study's statistical design. METHODS: In this global, partially blinded, randomised, controlled, phase 3 study, patients (aged ≥18 years) who had locally advanced or metastatic urothelial cancer previously untreated in the metastatic setting and Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 221 hospitals and oncology centres in 35 countries. Patients were randomly assigned (1:1:1), using a permuted block method (block size of six) and an interactive voice and web response system, stratified by PD-L1 status, Bajorin score, and investigator's choice of platinum-based chemotherapy, to receive either atezolizumab plus platinum-based chemotherapy (group A), atezolizumab alone (group B), or placebo plus platinum-based chemotherapy (group C). Sponsors, investigators, and patients were masked to assignment to atezolizumab or placebo in group A and group C; atezolizumab monotherapy in group B was open label. For groups B and C, atezolizumab (1200 mg) or placebo was administered intravenously every 3 weeks. Chemotherapy involved 21-day cycles of gemcitabine (1000 mg/m2 body surface area on day 1 and day 8 of each cycle) plus the investigator's choice of carboplatin (area under the curve 4·5 mg/mL per min or 5 mg/mL per min) or cisplatin (70 mg/m2 body surface area), administered intravenously. Co-primary endpoints were progression-free survival and overall survival in group A versus group C, and overall survival in group B versus group C, tested hierarchically, in the intention-to-treat (ITT) population, and then the populations with high PD-L1 tumour expression (immune cell [IC] expression score of IC2/3) if the results from group A versus group C were significant. Here, we report the co-primary endpoint of overall survival for group B versus group C in the ITT and IC2/3 populations. The ITT population for this analysis comprised concurrently enrolled patients in groups B and C who were randomly assigned to treatment. For the safety analysis, all patients enrolled in group B and group C who received any study treatment were included. The trial is registered with ClinicalTrials.gov, NCT02807636, and is active but no longer recruiting. FINDINGS: Between July 15, 2016, and July 20, 2018, 1213 patients were enrolled and randomly assigned to treatment, of whom 362 patients were assigned to group B and 400 to group C, of whom 360 and 359, respectively, were enrolled concurrently (ITT population). 543 (76%) of 719 patients were male, 176 (24%) were female, and 534 (74%) were White. As of data cutoff (Aug 31, 2022), after a median follow-up of 13·4 months (IQR 6·2-30·8), median overall survival was 15·2 months (95% CI 13·1-17·7; 271 deaths) in group B and 13·3 months (11·9-15·6; 275 deaths) in group C (stratified hazard ratio 0·98 [95% CI 0·82-1·16]). The most common grade 3-4 treatment-related adverse events were anaemia (two [1%] in patients who received atezolizumab monotherapy vs 133 [34%] in those who received placebo plus chemotherapy), neutropenia (one [<1%] vs 115 [30%]), decreased neutrophil count (0 vs 95 [24%]), and decreased platelet count (one [<1%] vs 92 [24%]). Serious adverse events occurred in 163 (46%) patients versus 196 (50%). Treatment-related deaths occurred in three (1%; n=1 each, pneumonia, interstitial lung disease, large intestinal obstruction) patients who received atezolizumab monotherapy and four (1%; n=1 each, diarrhoea, febrile neutropenia, unexplained death, toxic hepatitis) who received placebo plus chemotherapy. INTERPRETATION: The final analysis from IMvigor130 did not show a significant improvement in overall survival with first-line atezolizumab monotherapy compared with platinum-based chemotherapy in the intention-to-treat population. The safety profile of atezolizumab monotherapy remained acceptable after extended follow-up, with no new safety signals. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bamias A, Davis ID, Galsky MD, et al. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study. Lancet Oncol. 2023. PMID: 38101431. doi:10.1016/S1470-2045(23)00539-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。